Cipla First On Generic Nexium Formulation
Includes First 10mg Pediatric Formulation
India’s Cipla has received the first US approval for a generic rival to Nexium delayed-release oral suspension in the US. The firm recently declared its intention to direct funds to more complex formulations in the US but nevertheless continues to grow its vast portfolio in the market.
You may also be interested in...
Cipla is to moderate investments across its US generics R&D and specialty business, while its India business components – prescription, trade generic and consumer health – are being brought under a “single capital allocation framework.”
The US FDA has approved the first generic version of AstraZeneca's Nexium (esomeprazole magnesium delayed-release capsules) from Teva arm Ivax Pharmaceuticals, confirming Ranbaxy's fears that it had forfeited its 180-day exclusivity for the 20mg and 40mg versions of the product.
Korean firm Celltrion is aiming to move production of insulin pens inside Korea “for the first time” and break the stranglehold of Big Pharma insulin players in the market by launching a biosimilar product in 2025.